John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$172M |
| 2 |
Johnson & Johnson
JNJ
|
+$161M |
| 3 |
American Express
AXP
|
+$161M |
| 4 |
Apple
AAPL
|
+$156M |
| 5 |
Emerson Electric
EMR
|
+$150M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$172M |
| 2 |
AGN
Allergan Inc
AGN
|
+$139M |
| 3 |
Wynn Resorts
WYNN
|
+$111M |
| 4 |
AbbVie
ABBV
|
+$94.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$94.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 14.92% |
| 2 | Technology | 11.5% |
| 3 | Industrials | 10.9% |
| 4 | Healthcare | 10.87% |
| 5 | Consumer Staples | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Interface
TILE
$2.21B
| $4.68M | 0.02% |
225,119
+199,979
| +795% | +$3.6M |
|
752
Verisk Analytics
VRSK
$24.7B
| $4.67M | 0.02% |
+65,447
| New | +$4.42M |
|
753
Oxford Industries
OXM
$546M
| $4.67M | 0.02% |
61,860
+39,285
| +174% | +$2.21M |
|
|
ACOR
754
DELISTED
Acorda Therapeutics
ACOR
| $4.66M | 0.02% |
1,168
+1,031
| +753% | +$4.72M |
|
755
Pultegroup
PHM
$24.7B
| $4.64M | 0.02% |
208,837
-929,593
| -82% | -$20.2M |
|
756
Norwegian Cruise Line
NCLH
$7.91B
| $4.62M | 0.02% |
85,483
-32,885
| -28% | -$1.57M |
|
757
Arch Capital
ACGL
$34.5B
| $4.62M | 0.02% |
224,781
+205,200
| +1,048% | +$4.11M |
|
|
ANAT
758
DELISTED
American National Group, Inc. Common Stock
ANAT
| $4.6M | 0.02% |
46,778
+43,674
| +1,407% | +$4.49M |
|
|
VVC
759
DELISTED
Vectren Corporation
VVC
| $4.6M | 0.02% |
104,227
+53,773
| +107% | +$2.46M |
|
760
Copart
CPRT
$30.8B
| $4.59M | 0.02% |
978,456
-378,336
| -28% | -$1.75M |
|
761
1-800-Flowers.com
FLWS
$249M
| $4.59M | 0.02% |
388,142
+221,335
| +133% | +$2.26M |
|
|
LBY
762
DELISTED
Libbey, Inc.
LBY
| $4.59M | 0.02% |
114,961
+88,140
| +329% | +$3.11M |
|
763
PUT
EOG Resources
EOG
$78.8B
| $4.58M | 0.02% |
+50,000
| New | +$4.52M |
|
764
Integra LifeSciences
IART
$1.3B
| $4.58M | 0.02% |
181,895
+107,975
| +146% | +$2.55M |
|
|
DMND
765
DELISTED
DIAMOND FOODS, INC.
DMND
| $4.58M | 0.02% |
+140,597
| New | +$3.96M |
|
766
MKS Inc
MKSI
$18.2B
| $4.53M | 0.02% |
133,931
-5,067
| -4% | -$178K |
|
767
Oaktree Specialty Lending
OCSL
$1.16B
| $4.53M | 0.02% |
206,776
-211,812
| -51% | -$4.75M |
|
|
MACK
768
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $4.52M | 0.02% |
48,318
-2,447
| -5% | -$208K |
|
|
AMAG
769
DELISTED
AMAG Pharmaceuticals
AMAG
| $4.51M | 0.02% |
82,558
+19,536
| +31% | +$931K |
|
770
Gaming and Leisure Properties
GLPI
$12.8B
| $4.51M | 0.02% |
122,253
+90,930
| +290% | +$3.07M |
|
|
SKX
771
DELISTED
Skechers
SKX
| $4.48M | 0.02% |
187,062
-151,392
| -45% | -$3.26M |
|
772
CONMED
CNMD
$1.54B
| $4.46M | 0.02% |
88,347
+19,730
| +29% | +$967K |
|
773
GameStop
GME
$8.09B
| $4.46M | 0.02% |
+469,792
| New | +$4.42M |
|
774
Unifirst Corp
UNF
$5.28B
| $4.45M | 0.02% |
37,820
-37
| -0.1% | -$4.37K |
|
|
ATW
775
DELISTED
Atwood Oceanics
ATW
| $4.44M | 0.02% |
157,923
-385,993
| -71% | -$11.5M |
|
Similar funds
John Overdeck's Q1 2015 Portfolio in Review
As of Q1 2015, John Overdeck held 3,174 positions worth $21.5B, up 19% from $18.1B the previous quarter. Its ten largest holdings account for 7.3% of the portfolio.
John Overdeck deployed $3.03B of net new capital in Q1 2015, opening 981 new positions and adding to 805 existing holdings. Its largest new stake was Intel: 5,084,443 shares worth $159M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 10% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $94.4M trimmed.
- John Overdeck's largest Q1 2015 buy was Intel: 5,084,443 shares worth $159M.
- John Overdeck added most to Johnson & Johnson in Q1 2015, an estimated $161M increase.
- John Overdeck's biggest Q1 2015 reduction was AbbVie, cutting an estimated $94.4M.
- John Overdeck fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $172M.
- John Overdeck's ten largest holdings make up 7.3% of its $21.5B portfolio in Q1 2015.
- John Overdeck opened 981 new positions and closed 576 in Q1 2015.
- John Overdeck's portfolio value rose 19% quarter-over-quarter to $21.5B.
Based on Two Sigma Investments's 13F filing for Q1 2015, filed 15 May 2015.